Abstract
Diabetic neuropathy is the most common chronic complication of diabetes. The aim of the present study was to evaluate the protective effects of curcumin against neuropathy in gliclazide-treated diabetic rats. Diabetes was induced by an intraperitoneal injection of streptozotocin (45 mg/kg). Diabetic animals were given gliclazide (10 mg/kg, orally) alone or combined with curcumin (100 mg/kg, orally) or gabapentin (30 mg/kg, intraperitoneally as a positive control). Behavioral responses to thermal (hot plate and tail flick) and mechanical (tail pinch) pain, and some biochemical tests (serum glucose, C-peptide, peroxynitrite, lipid peroxides, and tumor necrosis factor-α) were assessed after 5 consecutive weeks of daily treatment. Combined treatment of curcumin with gliclazide significantly increased hot-plate and tail-flick latencies in comparison with that of the diabetic control group. The threshold of mechanical hyperalgesia was also significantly elevated. Serum glucose and C-peptide levels were significantly increased in the combined treatment compared with the diabetic control group, whereas serum levels of peroxynitrite, lipid peroxide, and tumor necrosis factor-α production were significantly decreased. The data suggest that the combination of curcumin with gliclazide may protect against the development of diabetic neuropathy, with favorable effects with respect to the gliclazide/gabapentin combination.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amines / administration & dosage
-
Amines / pharmacology
-
Amines / therapeutic use*
-
Analgesics / administration & dosage
-
Analgesics / pharmacology
-
Analgesics / therapeutic use
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Blood Glucose / drug effects
-
C-Peptide / blood
-
Curcumin / administration & dosage
-
Curcumin / pharmacology
-
Curcumin / therapeutic use*
-
Cyclohexanecarboxylic Acids / administration & dosage
-
Cyclohexanecarboxylic Acids / pharmacology
-
Cyclohexanecarboxylic Acids / therapeutic use*
-
Diabetes Mellitus, Experimental / blood
-
Diabetes Mellitus, Experimental / chemically induced
-
Diabetes Mellitus, Experimental / complications
-
Diabetes Mellitus, Experimental / drug therapy*
-
Diabetic Neuropathies / blood
-
Diabetic Neuropathies / prevention & control*
-
Drug Therapy, Combination / methods
-
Gabapentin
-
Gliclazide / administration & dosage
-
Gliclazide / pharmacology
-
Gliclazide / therapeutic use*
-
Hyperalgesia / drug therapy
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use
-
Lipid Peroxides / blood
-
Male
-
Pain Threshold / drug effects
-
Peroxynitrous Acid / blood
-
Rats
-
Rats, Sprague-Dawley
-
Tumor Necrosis Factor-alpha / blood
-
gamma-Aminobutyric Acid / administration & dosage
-
gamma-Aminobutyric Acid / pharmacology
-
gamma-Aminobutyric Acid / therapeutic use*
Substances
-
Amines
-
Analgesics
-
Anti-Inflammatory Agents, Non-Steroidal
-
Blood Glucose
-
C-Peptide
-
Cyclohexanecarboxylic Acids
-
Hypoglycemic Agents
-
Lipid Peroxides
-
Tumor Necrosis Factor-alpha
-
Peroxynitrous Acid
-
gamma-Aminobutyric Acid
-
Gabapentin
-
Gliclazide
-
Curcumin